Sinclair is a professor of genetics at Harvard Medical School and the founding director of the Paul F
Takeaway FDA approval for a GLP-1 drug to treat sleep apnea could come soon, some analysts predict
In some dogs, it may take six months to achieve glycemic control
Traditional weight loss methods don't work for everyone, especially when underlying factors like hormones, appetite regulation, or metabolic issues create barriers to success
In people with type 2 diabetes mellitus (T2DM), various changes occur in body composition, particularly in the form of increased visceral fat and decreased muscle and bone mass [6, 7]
Recently, GLP-1 agonists like Semaglutide have taken over the weight loss conversation as an innovative new option to consider